-
公开(公告)号：US20160347853A1
公开(公告)日：2016-12-01
申请号：US15204851
申请日：2016-07-07
Applicant: Innate Pharma
Inventor： Laurent Gauthier , Catherine Massacrier , Yannis Morel , Carine Paturel
IPC: C07K16/28 , A61K45/06 , A61K47/48 , A61K39/395
CPC classification number: C07K16/2896 , A61K39/3955 , A61K45/06 , A61K47/6849 , C07K2317/34 , C07K2317/35 , C07K2317/54 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention relates to antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind TLR3, and that optionally further modulate, e.g. inhibit, signaling. The invention also relates to cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same; methods of using the antibodies to diagnose, treat or prevent diseases, e.g. autoimmune diseases, inflammatory diseases and the like.
Abstract translation: 本发明涉及特异性结合TLR3的抗体（例如单克隆抗体），抗体片段及其衍生物，并且任选进一步调节，例如， 抑制信号。 本发明还涉及产生这种抗体的细胞; 制备此类抗体的方法; 抗体的片段，变体和衍生物; 包含它们的药物组合物; 使用抗体诊断，治疗或预防疾病的方法，例如， 自身免疫性疾病，炎症性疾病等。
-
公开(公告)号：US20160136272A1
公开(公告)日：2016-05-19
申请号：US14890921
申请日：2014-05-13
Applicant: INNATE PHARMA
Inventor： RENAUD BUFFET , CARINE PATUREL
IPC: A61K39/395 , C07K16/28 , A61K31/573
CPC classification number: A61K39/3955 , A61K31/573 , A61K2039/505 , C07K16/2896 , C07K2317/34 , C07K2317/76 , C07K2317/92 , C07K2317/94 , A61K31/00
Abstract: The present invention relates to use of therapeutic agents that specifically bind and inhibit TLR3 signalling in order to sensitize patients to treatment with corticosteroids, notably for the treatment and prevention of inflammatory and autoimmune disorders.
Abstract translation: 本发明涉及特异性结合和抑制TLR3信号传导的治疗剂的用途，以使患者敏感地用皮质类固醇治疗，特别是用于治疗和预防炎性和自身免疫性疾病。
-
公开(公告)号：US20160046713A1
公开(公告)日：2016-02-18
申请号：US14924786
申请日：2015-10-28
Applicant: INNATE PHARMA
Inventor： NICOLAS ANFOSSI , LAURENT GAUTHIER , YANNIS MOREL , ALESSANDRO MORETTA , SILVIA PAROLINI , BENJAMIN ROSSI
IPC: C07K16/28 , A61K45/06 , A61K39/395
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K16/3061 , C07K2317/24 , C07K2317/31 , C07K2317/34 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/732
Abstract: The present invention provides antigen-binding proteins capable of binding to KIR3D polypeptides. The antibodies have increased activity in the treatment of disorders characterized by KIR3DL2-expressing cells, particularly CD4+ T cells, including malignancies such as Mycosis Fungoides and Sézary Syndrome.
Abstract translation: 本发明提供能够结合KIR3D多肽的抗原结合蛋白。 抗体在治疗特征为表达KIR3DL2的细胞，特别是CD4 + T细胞，包括恶性肿瘤例如真菌病真菌和Sézary综合征的疾病中具有增加的活性。
-
公开(公告)号：US20150284713A1
公开(公告)日：2015-10-08
申请号：US14441157
申请日：2013-11-08
Applicant: INNATE PHARMA , PAUL SCHERRER INSTITUT
Inventor： Eliane Fischer , François Romagne , Patrick Dennler
CPC classification number: C12N15/1065 , A61K47/6889 , A61K47/6898 , B82Y5/00 , C07K2317/22 , C07K2317/569 , C07K2317/622 , C07K2318/00 , C07K2318/20 , C07K2319/41 , C07K2319/70 , C07K2319/90 , C12N15/1037 , C40B40/10
Abstract: The present application relates to methods for the functionalization of antibodies using transglutaminase, in particular antibodies lacking Fc regions. Also disclosed herein are peptide tags for transglutaminase, linking reagents, functionalized antibodies, multi-specific antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
Abstract translation: 本申请涉及使用转谷氨酰胺酶特异性抗体功能化的方法，特别是缺乏Fc区的抗体。 本文还公开了用于转谷氨酰胺酶，连接试剂，官能化抗体，多特异性抗体，药物组合物和治疗疾病和/或病症的方法的肽标签。
-
公开(公告)号：US09018366B2
公开(公告)日：2015-04-28
申请号：US13745081
申请日：2013-01-18
Applicant: Novo-Nordisk A/S—Novo Allé , Innate Pharma S.A.S.
Inventor： Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
CPC classification number: C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
Abstract: The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
Abstract translation: 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负信号可涉及配体结合诱导的KIR分子的构象重构，允许在特定结构域中的相邻KIR之间形成相互作用，导致加速 聚类 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来降低或阻断HLA结合。
-
Patent Agency Ranking
公开(公告)号：US08981065B2
公开(公告)日：2015-03-17
申请号：US13936486
申请日：2013-07-08
Applicant: Novo Nordisk A/S—Novo Alle , Innate Pharma S.A.S. , University of Genoa
Inventor： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Johannes Louis Spee , Michael Wilken
CPC classification number: C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
Abstract translation: 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20140356385A1
公开(公告)日：2014-12-04
申请号：US14367840
申请日：2012-12-21
Applicant: Innate Pharma , Paul Scherrer Institut
Inventor： Patrick Dennler , Delphine Bregeon , Laurent Gauthier , François Romagné , Christian Belmant , Eliane Fischer , Roger Schibli
CPC classification number: A61K47/6803 , A61K47/60 , A61K47/68 , A61K47/6807 , A61K47/6813 , A61K47/6817 , A61K47/6865 , A61K47/6871 , C07C217/08 , C07C223/02 , C07C229/26 , C07C233/62 , C07C247/04 , C07C323/12 , C07C323/60 , C07D225/08 , C07D257/08 , C07D277/06 , C07F9/5022 , C07K16/00 , C07K19/00 , C07K2317/40 , C12N9/1044 , C12P21/005 , G01N33/6854
Abstract: The present application relates to methods for the functionalization of immunoglobulins, in particular with drugs. Also disclosed herein are linking reagents, functionalized antibodies, pharmaceutical compositions, and method of treating disease and/or conditions.
Abstract translation: 本申请涉及用于免疫球蛋白功能化的方法，特别是与药物。 本文还公开了连接试剂，官能化抗体，药物组合物和治疗疾病和/或病症的方法。
-
公开(公告)号：US12209126B2
公开(公告)日：2025-01-28
申请号：US17054920
申请日：2019-05-14
Applicant: MEDIMMUNE LIMITED , INNATE PHARMA
Inventor： Shaad Essa Abdullah , Ashok Kumar Gupta , Xuyang Song
Abstract: The present invention relates to the use of NKG2A-neutralizing agents and PD-1 neutralizing agents to treat cancers, notable cancers that are not characterized by DNA mismatch repair deficiency. Provided are methods of treatment of a cancer, as well as compositions and kits useful for treating a cancer that is not characterized by DNA mismatch repair deficiency.
-
公开(公告)号：US20250002601A1
公开(公告)日：2025-01-02
申请号：US18568806
申请日：2022-06-08
Applicant: INNATE PHARMA
Inventor： LAURENT GAUTHIER , YANNIS MOREL , OLIVIER DEMARIA , BENJAMIN ROSSI
Abstract: The present invention relates to multispecific protein that binds to human NKp46, human CD20, human CD122, and optionally human CD16A. The protein according to the invention have utility in the treatment of disease, such as cancer.
-
70.发明公开公开(公告)号：US20240034816A1
公开(公告)日：2024-02-01
申请号：US18469947
申请日：2023-09-19
Applicant: SANOFI , INNATE PHARMA
Inventor： Nicolas GOURDIN , Laurent GAUTHIER , Alexandre TANG , Marielle CHIRON , Angela VIRONE-ODDOS , Alessandro MASIERO , Jochen BENINGA , Ingo FOCKEN , Sambasiva RAO , Yanfeng ZHOU , Leila SEVIGNY
CPC classification number: C07K16/468 , C12N15/63 , A61P35/00 , C07K2317/565 , C07K2317/522 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/41 , C07K2317/14 , C07K2317/31
Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor.
The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).
-
-
-
-
-
-
-
-
-
Search Results
183
records
(took 0.039 seconds)
